Chimerix raises $103.8 million in follow-on
Chimerix Inc. (NASDAQ:CMRX) raised $103.8 million through the sale of 7.3 million shares at $14.22 in a bumped-up follow-on underwritten by Morgan Stanley; JPMorgan; Cowen; William Blair; and Canaccord. Chimerix proposed to sell 6.2 million shares in the offering late Monday, when its share price was $16.82.
The company's brincidofovir is in Phase III testing for cytomegalovirus (CMV) infection in adults undergoing hematopoietic stem cell transplant (HSCT), with data expected in mid-2015. Next half, the company plans to start a Phase III trial to treat disseminated adenovirus infections. Brincidofovir is an oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the antiviral agent cidofovir diphosphate. ...